Jamie L. Wooldridge, MD
Appointment
Assistant Professor, Department of Pediatrics, Division of Pulmonary Medicine
Email
jamie.wooldridge@cchmc.org
Phone
513-636-6771
Fax
513-636-4615
Credentials
MD: Indiana University, Indianapolis, IN 1995.
Residency: Pediatrics, Indiana University, Indianapolis, IN, 1998.
Fellowship: Pediatric Pulmonology, University of Colorado Health Sciences Center, 2001.
Ceritification: Pediatrics, 1998; Pediatric Pulmonology, 2002.
Research
Cystic Fibrosis and lung inflammation
Research Grants and Contracts
Inspire Pharmaceuticals, Inc – A Multi-Centered, Double-Blind, Placebo-Controlled Randomized, Efficacy and Safety Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients with Mild Cystic Fibrosis Lung Disease. #08-108. Active
Boehringer Ingelheim Pharmaceuticals, Inc – A Randomized, Double-Blind within Dose, Placebo-Controlled Study to Investigate the Safety, Tolerability , and Pharmacokinetics of Increasing Single and Multiple Doses (28-day dosing) to Tiotropium Bromide Administered Once Daily via Respimat Device in Cystic Fibrosis Patients. #205-338. Active
Eurand, S.p.A. - An Open-Label Study to Evaluate the Safety and Efficacy of Eurand Pancreatic Enzyme Product (PEP) Microtabs" in Pediatric Patients with Cystic Fibrosis and Exocrine Pancreatic Insufficiency. EUR-1009-M
Eurnad S.p.A. - A Randomized, Double-Blind, Placebo-Controlled Two-Treatment, Crossover Study to Evaluate the Safety and Efficacy of Eurand Pancreatic Enzyme Product (PEP) in Patients With Cystic Fibrosis and Exocrine Pancreatic Insufficiency. EUR-1008-M
Gilead Pharmaceuticals, Inc.- A Phase 3, Double Blind, Multicenter, Multinational, Randomized, Placebo-Controlled Trial Evaluating Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients with Pulmonary P. aeruginosa #AIR-CF1. CHMC# 05-03-40
Gilead Pharmaceuticals, Inc.- A Phase 3, Open-Label, Follow-on Study of Multiple Course of Aztreonam Lysinate for Inhalation (AI) in Cystic Fibrosis Patients #AIR-CF3.
Publications, Most Recent
Elder DA, Wooldridge JL, Dolan LM, D'Alessio DA. Glucose Tolerance, Insulin Secretion and Insulin Sensitivity in Children and Adolescents with Cystic Fibrosis and No Prior History of Diabetes.J Pediatr (in press) 2007.
Prestridge A, Wooldridge JL, Deutsch G, Young LR, MD, Wert SR,Whitsett JA, Nogee L. Persistent Tachypnea and Hypoxia in a 3-month-old Term Infant.J Pediatr 2006;149:702-6.
Wooldridge JL, Deutsch GH, Sontag MK, Osberg I, Chase DR, Silkoff PE, Wagener JS, Accurso FJ. The NO pathway in CF and non-CF children. PediatrPulm 2004;37(4):338-50.
Wooldridge JL, Partrick DA, Bensard DD, Deterding RD. Diaphragmatic Hernia Simulating a Left Pleural Effusion. Pediatr 2003;112:e487-90.
Xu Y, Clark JC, Aranow BJ, Dey CR, Liu C, Wooldridge JL, Whitsett JA. Transcriptional Adaptation to CFTR Deficiency. J Biol Chem 2003;278:7674-82.
Professional Organization Memberships
American Thoracic SocietyAmerican Academy of PediatricsSpecial Interests
Cystic Fibrosis, Cystic Fibrosis Related Diabetes
Presentations, Most Recent:
Increased expression and cellular localization of S100A8 and A9 in lungs from CFTR -/- mice. North American Cystic Fibrosis Foundation Conference. Innate Immunity Workshop, 2003.
Nitric Oxide in Children with CF. Visiting Lectureship Speaker, Rainbow Babies and Children's Hospital; Cleveland, OH; December, 2001.
Microarray determination of Gene expression in Cystic Fibrosis (CF) and Control Whole Lung Tissue. American Thoracic Society International Conference. Potential Therapies and Emerging Technologies for Cystic Fibrosis Poster Discussion Session; 2001
Panbronchiolitis in a Patient with a Single CFTR Mutation Pediatric Fellows Session, North American Cystic Fibrosis Foundation Conference; 2000.
Related Areas
This person works in these other areas at Cincinnati Children's Hospital Medical Center:
